Macrogen Inc (038290) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.042x

Based on the latest financial reports, Macrogen Inc (038290) has a cash flow conversion efficiency ratio of 0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩7.10 Billion ≈ $4.81 Million USD) by net assets (₩168.36 Billion ≈ $114.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Macrogen Inc market cap and net worth for the company's overall valuation and market capitalisation.

Macrogen Inc - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Macrogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Macrogen Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Macrogen Inc ranked by their cash flow conversion efficiency. Explore 038290 operating cash flow to net income to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Quantum Graphite Ltd
AU:QGL
-0.115x
VLS Finance Limited
NSE:VLSFINANCE
-0.002x
CSP Inc
NASDAQ:CSPI
-0.011x
Klevo Rewards Limited
AU:KLV
N/A
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
0.156x
Houston American Energy Corporation
NYSE MKT:HUSA
-0.108x
Kalleback Property Invest AB
ST:KAPIAB
0.049x
Knafaim
TA:KNFM
0.023x

Annual Cash Flow Conversion Efficiency for Macrogen Inc (2011–2024)

The table below shows the annual cash flow conversion efficiency of Macrogen Inc from 2011 to 2024. View latest Macrogen Inc stock price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩177.43 Billion
≈ $120.24 Million
₩7.12 Billion
≈ $4.83 Million
0.040x +34.13%
2023-12-31 ₩159.19 Billion
≈ $107.88 Million
₩4.77 Billion
≈ $3.23 Million
0.030x -50.14%
2022-12-31 ₩179.32 Billion
≈ $121.52 Million
₩10.77 Billion
≈ $7.30 Million
0.060x -43.13%
2021-12-31 ₩200.64 Billion
≈ $135.97 Million
₩21.18 Billion
≈ $14.36 Million
0.106x +1.79%
2020-12-31 ₩198.15 Billion
≈ $134.28 Million
₩20.55 Billion
≈ $13.93 Million
0.104x -18.91%
2019-12-31 ₩113.33 Billion
≈ $76.80 Million
₩14.50 Billion
≈ $9.82 Million
0.128x -3.28%
2018-12-31 ₩118.01 Billion
≈ $79.98 Million
₩15.61 Billion
≈ $10.58 Million
0.132x -4.58%
2017-12-31 ₩94.28 Billion
≈ $63.89 Million
₩13.07 Billion
≈ $8.86 Million
0.139x -46.15%
2016-12-31 ₩82.55 Billion
≈ $55.94 Million
₩21.25 Billion
≈ $14.40 Million
0.257x +173.79%
2015-12-31 ₩76.11 Billion
≈ $51.58 Million
₩7.15 Billion
≈ $4.85 Million
0.094x -4.15%
2014-12-31 ₩67.13 Billion
≈ $45.49 Million
₩6.58 Billion
≈ $4.46 Million
0.098x -35.74%
2013-12-31 ₩60.05 Billion
≈ $40.69 Million
₩9.16 Billion
≈ $6.21 Million
0.153x -28.37%
2012-12-31 ₩51.71 Billion
≈ $35.05 Million
₩11.02 Billion
≈ $7.47 Million
0.213x -17.57%
2011-12-31 ₩43.11 Billion
≈ $29.21 Million
₩11.14 Billion
≈ $7.55 Million
0.258x --

About Macrogen Inc

KQ:038290 Korea Biotechnology & Medical Research
Market Cap
$79.80 Million
₩117.75 Billion KRW
Market Cap Rank
#20165 Global
#1075 in Korea
Share Price
₩11750.00
Change (1 day)
-0.42%
52-Week Range
₩10700.00 - ₩19520.00
All Time High
₩49726.89
About

Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing ser… Read more